ImmunityBio, Inc. Common Stock

IBRXNASDAQ • USD
10.29 USD
↗ 1.01 (10.83%)AT CLOSE (03:59 PM EDT)
10.30
↗ 0.02 (0.15%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
10.30
↗ 0.02 (0.15%)
🔴Market: CLOSED

IBRX is currently priced at $10.29. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (94.8%), a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Oct 2, 2026.

Open?$9.39
High?$10.55
Low?$9.39
Prev. Close?$9.28
Volume?31.3M
Avg. Volume?11.3M
VWAP?$10.22
Rel. Volume?2.76x
Bid / Ask
Bid?$10.29 × 200
Ask?$10.30 × 500
Spread?$0.01
Midpoint?$10.30
Valuation & Ratios
Market Cap?10.9B
Shares Out?1.1B
Float?395.0M
Float %?37.3%
P/E Ratio?N/A
P/B Ratio?-10.42
EPS?-$0.94
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Employees
691
Market Cap
9.8B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-03-10
Address
3530 JOHN HOPKINS COURT
SAN DIEGO, CA 92121
Phone: (844) 696-5235
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
87
Short Sent.?
30
Piotroski F-Score?3/9Weak
Altman Z-Score?-6.68Distress
Confidence?58%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?31.75%Squeeze Risk
Short Interest?125.4M
Days to Cover?15.9
Free Float395.0M
Avg Daily Volume7.9M
Settlement Date2026-09-15
Financial Health
Current Ratio?5.72Strong
Quick Ratio?5.70Strong
Cash Ratio?0.99Adequate
Debt/Equity?-0.40Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
S&P
97
-10.42CHEAP▾
P/S?
Peers
100
S&P
3
65.78HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-47.8CHEAP▾
EV/Sales?
Peers
100
S&P
3
67.83HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
94.8%STRONG▾
ROA?
S&P
3
-157.9%WEAK▾
Cash Flow & Enterprise
FCF?$-288074000
Enterprise Value?$11.2B
Fundamentals ratios updated end of day